Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Kira Starts Trial of Candidate for Complement-Mediated Diseases

publication date: Feb 3, 2021

Kira Pharma, a global biotech developing complement-targeted therapies for immune-mediated diseases, dosed the first healthy volunteer in a Phase I trial of P014, its lead candidate. P014 is a novel bi-functional biologic that is designed to block two separate rate-limiting steps in the complement activation cascade. The company plans to test P014 in several complement-mediated diseases. In late 2020, Kira closed a $53 million Series B+ financing. The company is headquartered in Cambridge, MA with R&D operations in Suzhou. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital